Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Factors that influence radioactive iodine use for thyroid cancer.

Papaleontiou M, Banerjee M, Yang D, Sisson JC, Koenig RJ, Haymart MR.

Thyroid. 2013 Feb;23(2):219-24. doi: 10.1089/thy.2012.0380.

2.

Surgeon training and use of radioactive iodine in stage I thyroid cancer patients.

Schuessler KM, Banerjee M, Yang D, Stewart AK, Doherty GM, Haymart MR.

Ann Surg Oncol. 2013 Mar;20(3):733-8. doi: 10.1245/s10434-012-2745-0. Epub 2012 Dec 6.

3.

The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer.

Haymart MR, Banerjee M, Yang D, Stewart AK, Koenig RJ, Griggs JJ.

Cancer. 2013 Jan 15;119(2):259-65. doi: 10.1002/cncr.27721. Epub 2012 Jun 28.

4.

The relationship between extent of thyroid cancer surgery and use of radioactive iodine.

Haymart MR, Banerjee M, Yang D, Stewart AK, Doherty GM, Koenig RJ, Griggs JJ.

Ann Surg. 2013 Aug;258(2):354-8. doi: 10.1097/SLA.0b013e31826c8915.

5.

Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.

Sacks W, Wong RM, Bresee C, Braunstein GD.

Thyroid. 2015 Apr;25(4):377-85. doi: 10.1089/thy.2014.0298. Epub 2015 Feb 6.

PMID:
25578116
6.

Disease severity and radioactive iodine use for thyroid cancer.

Haymart MR, Muenz DG, Stewart AK, Griggs JJ, Banerjee M.

J Clin Endocrinol Metab. 2013 Feb;98(2):678-86. doi: 10.1210/jc.2012-3160. Epub 2013 Jan 15.

7.

Use of radioactive iodine for thyroid cancer.

Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ.

JAMA. 2011 Aug 17;306(7):721-8. doi: 10.1001/jama.2011.1139.

8.

Radioactive iodine remnant uptake after completion thyroidectomy: not such a complete cancer operation.

Oltmann SC, Schneider DF, Leverson G, Sivashanmugam T, Chen H, Sippel RS.

Ann Surg Oncol. 2014 Apr;21(4):1379-83. doi: 10.1245/s10434-013-3450-3. Epub 2013 Dec 31.

9.

Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey.

Sawka AM, Goldstein DP, Thabane L, Brierley JD, Tsang RW, Rotstein L, Kamalanathan S, Zhao B, Gafni A, Straus S, Ezzat S.

Endocr Pract. 2008 Mar;14(2):175-84.

PMID:
18308655
10.

The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008.

Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD.

Thyroid. 2010 Nov;20(11):1235-45. doi: 10.1089/thy.2009.0455. Review.

PMID:
21062195
11.

Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow-up from a decision-aid randomized trial.

Sawka AM, Straus S, Rodin G, Heus L, Brierley JD, Tsang RW, Rotstein L, Ezzat S, Segal P, Gafni A, Thorpe KE, Goldstein DP.

Cancer. 2015 Oct 15;121(20):3717-26. doi: 10.1002/cncr.29548. Epub 2015 Jul 20.

12.

Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States.

Sawka AM, Rotstein L, Brierley JD, Tsang RW, Thabane L, Gafni A, Straus S, Kamalanathan S, Zhao B, Goldstein DP, Rambaldini G, Ezzat S.

Thyroid. 2007 Dec;17(12):1235-42.

PMID:
17988197
13.

The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.

Zevallos JP, Xu L, Yiu Y.

Thyroid. 2014 Apr;24(4):758-63. doi: 10.1089/thy.2013.0409. Epub 2014 Feb 3.

PMID:
24378070
14.

Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.

Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffé S, Pochart JM, Cochet I, Crevisy E, Dalac A, Papathanassiou D, Toubeau M.

J Clin Endocrinol Metab. 2012 May;97(5):1526-35. doi: 10.1210/jc.2011-2512. Epub 2012 Feb 16.

PMID:
22344193
15.

Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer: update to study protocol with follow-up extension.

Sawka AM, Straus S, Rodin G, Thorpe KE, Ezzat S, Gafni A, Goldstein DP.

Trials. 2015 Jul 14;16:302. doi: 10.1186/s13063-015-0819-6.

16.

Adjuvant radioactive iodine use among differentiated thyroid cancer patients in the military health system.

Gill AA, Enewold L, Zahm SH, Shriver CD, Zheng L, McGlynn KA, Zhu K.

Mil Med. 2014 Sep;179(9):1043-50. doi: 10.7205/MILMED-D-13-00540.

PMID:
25181724
17.

Referral patterns for patients with high-risk thyroid cancer.

Haymart MR, Banerjee M, Yang D, Stewart AK, Griggs JJ, Sisson JC, Koenig RJ.

Endocr Pract. 2013 Jul-Aug;19(4):638-43. doi: 10.4158/EP12288.OR.

18.

Variation in the management of thyroid cancer.

Haymart MR, Banerjee M, Yang D, Stewart AK, Sisson JC, Koenig RJ, Doherty GM, Griggs JJ.

J Clin Endocrinol Metab. 2013 May;98(5):2001-8. doi: 10.1210/jc.2012-3355. Epub 2013 Mar 28.

19.

A usability study of a computerized decision aid to help patients with, early stage papillary thyroid carcinoma in, decision-making on adjuvant radioactive iodine treatment.

Sawka AM, Straus S, Gafni A, Meiyappan S, O'Brien MA, Brierley JD, Tsang RW, Rotstein L, Thabane L, Rodin G, George SR, Goldstein DP.

Patient Educ Couns. 2011 Aug;84(2):e24-7. doi: 10.1016/j.pec.2010.07.038. Epub 2010 Aug 21.

PMID:
20732775
20.

Thyroid cancer patients' involvement in adjuvant radioactive iodine treatment decision-making and decision regret: an exploratory study.

Sawka AM, Straus S, Gafni A, Meiyappan S, David D, Rodin G, Brierley JD, Tsang RW, Thabane L, Rotstein L, Ezzat S, Goldstein DP.

Support Care Cancer. 2012 Mar;20(3):641-5. doi: 10.1007/s00520-011-1302-x. Epub 2011 Nov 10.

Supplemental Content

Support Center